To support research collaborations between the US and India that focus on the basic biology and/or genetics of ophthalmic diseases, the Department of Biotechnology (DBT) and the Department of Health & Human Services, Government of the United States of America, will soon begin joint research in the area of eye diseases.
Earlier, the DBT had signed a Statement of Intent on Indo-US Collaboration on Expansion of Vision Research with the Department of Health & Human Services, Government of the United States of America, with the objective of translating research outcomes to develop potential interventions to reduce eye disease burden in India and the USA.
The DBT has now invited joint research proposals from eligible scientists under this Indo-US collaborative expansion of vision research programme. The last date for receiving application is 9th November, 2017.
This call is intended to support research collaborations between the US and India that focus on the basic biology and/or genetics of ophthalmic diseases. Applications may be derived from existing collaborations with an established history of interaction, or from new partnerships developed in response to this call. The collaboration must be based on interactive relationships that maximize the expertise of the individual U.S. and Indian research teams and interactions between their parent institutions and granting agencies.
Joint research proposals are accordingly invited from interested researchers under the Indo-US collaborative programme on Vision Research especially under the research areas identified as high priority for funding such as Diabetic Retinopathy, Genetics of Ophthalmic Diseases and Ocular Inflammation.
The Indian side principal investigator (PI) has to provide a 2-3 page document, from the US partner, in the proposal consisting of the objectives, methodology, the need for and the role of the Indian PI, and the timelines of the US side proposal along with the IPR issues as well as justification for Indo-US collaboration. Investigators in USA should follow RO1 application guidelines and applications should be submitted to NEI/NIH directly.
Source : www.pharmabizz.com
Published on: November 7, 2017